DK3071215T3 - Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension - Google Patents
Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension Download PDFInfo
- Publication number
- DK3071215T3 DK3071215T3 DK14864524.5T DK14864524T DK3071215T3 DK 3071215 T3 DK3071215 T3 DK 3071215T3 DK 14864524 T DK14864524 T DK 14864524T DK 3071215 T3 DK3071215 T3 DK 3071215T3
- Authority
- DK
- Denmark
- Prior art keywords
- compositions
- treatment
- methods
- pulmonal
- hypertension
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361907260P | 2013-11-21 | 2013-11-21 | |
PCT/US2014/066776 WO2015077540A2 (en) | 2013-11-21 | 2014-11-21 | Compositions and methods for treating pulmonary hypertension |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3071215T3 true DK3071215T3 (da) | 2020-03-23 |
Family
ID=53180397
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14864524.5T DK3071215T3 (da) | 2013-11-21 | 2014-11-21 | Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension |
DK20150385.1T DK3685848T3 (da) | 2013-11-21 | 2014-11-21 | Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK20150385.1T DK3685848T3 (da) | 2013-11-21 | 2014-11-21 | Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension |
Country Status (9)
Country | Link |
---|---|
US (2) | US10682392B2 (da) |
EP (3) | EP3685848B1 (da) |
JP (3) | JP6640083B2 (da) |
CN (1) | CN105934249A (da) |
AU (3) | AU2014352843B2 (da) |
CA (1) | CA2931309C (da) |
DK (2) | DK3071215T3 (da) |
ES (2) | ES2902533T3 (da) |
WO (1) | WO2015077540A2 (da) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105658672A (zh) | 2013-08-22 | 2016-06-08 | 阿塞勒隆制药公司 | TGF-β受体II型变体及其用途 |
CN105934249A (zh) * | 2013-11-21 | 2016-09-07 | 布里格姆及妇女医院股份有限公司 | 用于治疗肺高压的组合物和方法 |
CN114470207B (zh) * | 2014-08-01 | 2023-09-19 | 布里格姆及妇女医院股份有限公司 | 与肺动脉高压的治疗有关的组合物和方法 |
CA2994413A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma, Inc. | Methods for treating myeloproliferative disorders |
US20200231652A1 (en) * | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
WO2018013936A1 (en) | 2016-07-15 | 2018-01-18 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
CA3038526A1 (en) * | 2016-09-27 | 2018-04-05 | Epicentrx, Inc. | Immunomodulatory fusion proteins |
KR20190129896A (ko) | 2017-03-02 | 2019-11-20 | 내셔날 리서치 카운실 오브 캐나다 | Tgf-β-수용체 엑토도메인 융합 분자 및 그의 용도 |
KR102635723B1 (ko) | 2017-05-04 | 2024-02-08 | 악셀레론 파마 인코포레이티드 | Tgf-베타 수용체 유형 ii 융합 단백질 및 이의 용도 |
CA3061791A1 (en) | 2017-05-12 | 2019-10-29 | Jiangsu Hengrui Medicine Co., Ltd. | Fusion protein containing tgf-.beta. receptor and medicinal uses thereof |
CN111511769B (zh) | 2017-09-27 | 2024-05-24 | 埃皮辛特瑞柯斯公司 | 免疫调节性融合蛋白 |
MX2020009394A (es) | 2018-03-09 | 2021-01-15 | Agenus Inc | Anticuerpos anti-cd73 y métodos de uso de los mismos. |
CN111867612A (zh) * | 2018-03-26 | 2020-10-30 | 阿尔托生物科学有限责任公司 | 抗PDL1、IL-15和TGF-β受体组合分子 |
US20220017601A1 (en) | 2018-11-09 | 2022-01-20 | Jiangsu Hengrui Medicine Co., Ltd. | TGF-beta RECEPTOR FUSION PROTEIN PHARMACEUTICAL COMPOSITION AND USE THEREOF |
WO2021021528A1 (en) * | 2019-07-26 | 2021-02-04 | Board Of Trustees Of Michigan State University | Methods of preventing or treating fatty degeneration of skeletal muscle |
EP4021928A4 (en) * | 2019-08-29 | 2023-09-20 | NantBio, Inc. | MODIFIED N-810 AND ASSOCIATED METHODS |
TW202128763A (zh) * | 2019-11-12 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含有TGF-β受體的融合蛋白及其醫藥用途 |
WO2023206188A1 (en) * | 2022-04-28 | 2023-11-02 | Wenzhou Prarucom Bio-Chemical Technology Co. | Method for alleviating pulmonary fibrosis using epidermal growth factor |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
ES2289778T3 (es) | 1997-04-18 | 2008-02-01 | Biogen Idec Ma Inc. | Proteinas de fusion de la region constante de la inmunoglobulina/receptor tgf-beta tipo ii. |
US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
AU4572899A (en) | 1998-06-16 | 2000-01-05 | Biogen, Inc. | Variant type ii tgf-beta receptor fusion proteins and methods |
ES2146552B1 (es) | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
US7157235B2 (en) | 2002-06-17 | 2007-01-02 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
ATE396068T1 (de) * | 2002-10-14 | 2008-06-15 | Michelin Soc Tech | Wulst mit symmetrischer kraftverteilung für einen notlaufreifen |
WO2005010049A2 (en) * | 2003-07-09 | 2005-02-03 | Eli Lilly And Company | Tgf-beta1 ligands |
GB0514259D0 (en) | 2005-07-12 | 2005-08-17 | Renovo Ltd | Pharmaceutical compositions |
WO2007108992A2 (en) | 2006-03-13 | 2007-09-27 | The Johns Hopkins University | Augmentation of endothelial thromboresistance |
JP2009539842A (ja) | 2006-06-05 | 2009-11-19 | ノバルティス アクチエンゲゼルシャフト | 副甲状腺関連障害の処置におけるTGF−βアンタゴニストの使用 |
CN100588717C (zh) | 2007-03-21 | 2010-02-10 | 中国医学科学院阜外心血管病医院 | 生长分化因子15基因多态位点在预测高血压继发左心室肥厚中的用途 |
JP5303557B2 (ja) | 2007-08-22 | 2013-10-02 | アイアールエム・リミテッド・ライアビリティ・カンパニー | キナーゼ阻害剤である2−ヘテロアリールアミノ−ピリミジン誘導体 |
EP2037275A1 (en) | 2007-09-11 | 2009-03-18 | F. Hoffmann-La Roche AG | Differentiation of different causes of right heart failure |
WO2010031168A1 (en) | 2008-09-17 | 2010-03-25 | National Research Council Of Canada | HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY |
KR101008385B1 (ko) | 2008-08-01 | 2011-01-14 | 한국과학기술연구원 | 다환 방향족 탄화수소류 노출 여부 확인용 바이오마커 및이를 이용한 확인 방법 |
WO2011088148A1 (en) | 2010-01-12 | 2011-07-21 | Isis Pharmaceuticals, Inc. | Modulation of transforming growth factor-beta 1 expression |
EP2372364A1 (en) | 2010-03-31 | 2011-10-05 | Medizinische Hochschule Hannover | Biomarker for pulmonary hypertension |
US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
US20130287688A1 (en) | 2010-11-18 | 2013-10-31 | Xtuit Pharmaceuticals, Inc. | Novel compositions and uses of anti-hypertension agents for cancer therapy |
WO2012093125A1 (en) * | 2011-01-06 | 2012-07-12 | Glaxo Group Limited | Ligands that bind tgf-beta receptor ii |
JP6250533B2 (ja) * | 2011-04-20 | 2017-12-20 | アクセレロン ファーマ インコーポレイテッドAcceleron Pharma,Inc. | エンドグリンポリペプチドおよびその使用 |
BR112013030958B1 (pt) | 2011-06-03 | 2022-02-08 | Xoma Technology Ltd | Anticorpo que se liga ao fator de transformação de crescimento beta, composição farmacêutica, usos dos mesmos, molécula de ácido nucleico, vetor de expressão, e método para produção de um anticorpo |
WO2013019805A1 (en) * | 2011-08-01 | 2013-02-07 | Tufts Medical Center, Inc. | Treatment of heart failure and related conditions |
CN102321173B (zh) | 2011-08-12 | 2013-04-03 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
WO2013059879A1 (en) | 2011-10-26 | 2013-05-02 | Howard Florey Institute Of Experimental Physiology And Medicine | Compositions and methods for the treatment of fibrosis and fibrotic diseases |
US9388412B2 (en) | 2012-06-15 | 2016-07-12 | The General Hospital Corporation | Inhibitors of microRNAs that regulate production of atrial natriuretic peptide (ANP) as therapeutics and uses thereof |
EP2597466A1 (en) | 2012-06-26 | 2013-05-29 | Roche Diagniostics GmbH | Means and methods for proSP-B based diagnosis of alveolar damage in pulmonary hypertension patients |
EP3590537A1 (en) | 2012-09-26 | 2020-01-08 | Julius-Maximilians-Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) |
AR094271A1 (es) | 2012-12-21 | 2015-07-22 | Aveo Pharmaceuticals Inc | Anticuerpos anti-gdf15 |
CA2898128A1 (en) | 2013-01-17 | 2014-07-24 | Medizinische Hochschule Hannover | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases |
KR101346181B1 (ko) | 2013-02-18 | 2014-01-03 | 강원대학교산학협력단 | Mic-1의 혈관신생유도 기능을 억제하는 항 mic-1 단일클론항체 mbm-12 |
KR101346132B1 (ko) | 2013-02-18 | 2013-12-31 | 강원대학교산학협력단 | Mic-1의 혈관신생유도 기능을 억제하는 항 mic-1 단일클론항체 mbm-14 |
CN105658672A (zh) * | 2013-08-22 | 2016-06-08 | 阿塞勒隆制药公司 | TGF-β受体II型变体及其用途 |
CN105934249A (zh) * | 2013-11-21 | 2016-09-07 | 布里格姆及妇女医院股份有限公司 | 用于治疗肺高压的组合物和方法 |
CN113817672A (zh) | 2014-05-18 | 2021-12-21 | 儿童医学中心公司 | 涉及外排体的方法和组合物 |
CA2952061A1 (en) | 2014-06-13 | 2015-12-17 | Novartis Ag | Use of serelaxin to reduce gdf-15 |
WO2015196142A1 (en) | 2014-06-20 | 2015-12-23 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
CN114470207B (zh) * | 2014-08-01 | 2023-09-19 | 布里格姆及妇女医院股份有限公司 | 与肺动脉高压的治疗有关的组合物和方法 |
CA2994413A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma, Inc. | Methods for treating myeloproliferative disorders |
-
2014
- 2014-11-21 CN CN201480073820.1A patent/CN105934249A/zh active Pending
- 2014-11-21 WO PCT/US2014/066776 patent/WO2015077540A2/en active Application Filing
- 2014-11-21 JP JP2016533067A patent/JP6640083B2/ja active Active
- 2014-11-21 EP EP20150385.1A patent/EP3685848B1/en active Active
- 2014-11-21 CA CA2931309A patent/CA2931309C/en active Active
- 2014-11-21 US US15/037,852 patent/US10682392B2/en active Active
- 2014-11-21 EP EP21190858.7A patent/EP4005585B1/en active Active
- 2014-11-21 DK DK14864524.5T patent/DK3071215T3/da active
- 2014-11-21 ES ES20150385T patent/ES2902533T3/es active Active
- 2014-11-21 ES ES14864524T patent/ES2778201T3/es active Active
- 2014-11-21 AU AU2014352843A patent/AU2014352843B2/en active Active
- 2014-11-21 DK DK20150385.1T patent/DK3685848T3/da active
- 2014-11-21 EP EP14864524.5A patent/EP3071215B1/en active Active
-
2019
- 2019-12-25 JP JP2019233811A patent/JP6952100B2/ja active Active
-
2020
- 2020-04-17 US US16/851,287 patent/US11951156B2/en active Active
- 2020-05-12 AU AU2020203110A patent/AU2020203110A1/en not_active Abandoned
-
2021
- 2021-09-27 JP JP2021156343A patent/JP7474729B2/ja active Active
-
2023
- 2023-11-12 AU AU2023263573A patent/AU2023263573A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3685848A1 (en) | 2020-07-29 |
US11951156B2 (en) | 2024-04-09 |
AU2014352843B2 (en) | 2020-03-05 |
AU2020203110A1 (en) | 2020-06-11 |
EP4005585B1 (en) | 2024-03-27 |
JP2017501977A (ja) | 2017-01-19 |
US20160287664A1 (en) | 2016-10-06 |
JP6952100B2 (ja) | 2021-10-20 |
EP3071215A4 (en) | 2017-08-23 |
JP2020073528A (ja) | 2020-05-14 |
WO2015077540A2 (en) | 2015-05-28 |
CA2931309A1 (en) | 2015-05-28 |
JP7474729B2 (ja) | 2024-04-25 |
CN105934249A (zh) | 2016-09-07 |
JP6640083B2 (ja) | 2020-02-05 |
CA2931309C (en) | 2022-06-21 |
AU2014352843A1 (en) | 2016-06-16 |
DK3685848T3 (da) | 2021-12-13 |
ES2778201T3 (es) | 2020-08-10 |
EP3685848B1 (en) | 2021-09-15 |
JP2021193139A (ja) | 2021-12-23 |
ES2902533T3 (es) | 2022-03-28 |
US10682392B2 (en) | 2020-06-16 |
AU2023263573A1 (en) | 2023-11-30 |
EP3071215A2 (en) | 2016-09-28 |
WO2015077540A3 (en) | 2015-11-19 |
EP3071215B1 (en) | 2020-01-08 |
EP4005585A1 (en) | 2022-06-01 |
US20200323955A1 (en) | 2020-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3071215T3 (da) | Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension | |
DK3556869T3 (da) | Sammensætninger og fremgangsmåder til sekventering af polynukleotider | |
DK2961831T3 (da) | Sammensætninger og fremgangsmåder til immunterapi | |
DK3212778T3 (da) | Fremgangsmåder og sammensætninger til stabilisering af trans-splejsning af intein-modificerede proteaser | |
DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
DK2929031T5 (da) | Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf | |
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
DK3212226T3 (da) | Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser | |
DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
DK3008168T3 (da) | Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf | |
DK2970456T3 (da) | Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer | |
DK3087095T3 (da) | FcRn-antagonist og fremgangsmåder til anvendelse | |
DK3080100T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
DK2958588T3 (da) | Kombination af vaccination og hæmning af PD-1-reaktionsvejen | |
DK3080274T3 (da) | Fremgangsmåder og sammensætninger til genom-manipulation | |
DK2898061T3 (da) | Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande | |
DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
DK2978419T3 (da) | Sammensætninger til forbedring af cellelevedygtighed og fremgangsmåder til anvendelse deraf | |
DK3007695T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
DK2776567T3 (da) | Sammensætninger og fremgangsmåder til behandling af cytomegalovirus. | |
DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
DK2872153T3 (da) | Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf | |
DK2739293T3 (da) | Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus | |
DK2768321T3 (da) | Fremgangsmåder og sammensætninger til induktion af mæthed | |
DK3087184T3 (da) | Fremgangsmåder og sammensætninger til specifik inhibering af glycolatoxidase (hao1) med dobbeltstrenget rna |